The Impacts of Clozapine Use on the Risk and Outcomes of COVID-19 Disease in Patients with Schizophrenia.
| Autor: | Özdemir M; Kanuni Sultan Süleyman Training and Research Hospital, Department of Psychiatry, İstanbul, Turkey., Yıldırım YE; University of Health Sciences, Bakırköy Mazhar Osman Training and Research Hospital for Psychiatric and Neurological Diseases, Department of Psychiatry, İstanbul, Turkey., Kart A; University of Health Sciences, Bakırköy Mazhar Osman Training and Research Hospital for Psychiatric and Neurological Diseases, Department of Psychiatry, İstanbul, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Noro psikiyatri arsivi [Noro Psikiyatr Ars] 2023 May 02; Vol. 60 (2), pp. 99-103. Date of Electronic Publication: 2023 May 02 (Print Publication: 2023). |
| DOI: | 10.29399/npa.28317 |
| Abstrakt: | Introduction: Clozapine may affect the outcome of severe COVID-19 infection due to its anti-inflammatory and immunosuppressant effects. This study aimed to investigate whether the risk of COVID-19 changed in schizophrenic patients using clozapine and to compare patients using clozapine with other antipsychotics in terms of COVID-19 severity. Methods: A total of 732 patients who were registered and followed up with a diagnosis of schizophrenia were included in the study. These patients' sociodemographic data, smoking status, medications, comorbidities, COVID-19 PCR results, and COVID-19 outcomes (inpatient care admission, intensive care unit admission, death) were retrospectively analyzed. Results: Of the 732 patients included in our study, 177 were using clozapine. Ninety-six of 732 patients were diagnosed with COVID-19, and 34 of these were being treated with clozapine. We found that clozapine use was an independent risk factor for COVID-19 positivity (OR=1.81 95% CI=1.13-2.90), inpatient care admission (OR=3.01, 95% CI=1.12-8.06). Conclusion: In our study, clozapine use was associated with an increased risk of COVID-19 positivity and inpatient care admission; however, it was not associated with ICU admission or death. Due to the frequent follow-up of patients using clozapine and the effects of clozapine on immunity, the frequency and/or identification of COVID-19 may be increased in these patients. Clozapine toxicity, granulocytopenia or agranulocytosis during the COVID-19 infection may have increased these patients' hospitalisation frequency. Competing Interests: Conflict of Interest: The authors declared that there is no conflict of interest. (Copyright: © 2023 Turkish Neuropsychiatric Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|